Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 9;32(10):645.
doi: 10.1007/s00520-024-08839-y.

Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer

Onam Ok  1 , Mangyeong Lee  2   3 , Nayeon Kim  1   2   4 , Juhee Cho  2   3   4 , Sun Young Hong  1 , Min Sun Nam  1 , Mi Sun Yi  1 , Dongryul Oh  5 , Jin Seok Ahn  6 , Danbee Kang  7   8   9 , Jeong Hee Hong  10
Affiliations

Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer

Onam Ok et al. Support Care Cancer. .

Abstract

Purpose: This study has a purpose to investigate the side effects of three EGFR-TKIs targeted therapeutic agents (gefitinib, erlotinib, and afatinib) and all-cause mortality in patients with metastatic lung cancer.

Methods: We performed a prospective cohort study. We selected all patients with newly diagnosed metastatic lung cancer between January and November 2019. Main exposure was daytime versus nighttime use of targeted EGFR TKIs. The study outcome was a symptom change using the mobile application, and all-cause mortality between January 2019 and March 2023.

Results: Among the 87 study participants, 35 (40%) took their medication at night. Among the 87 study participants, 35 (40%) took their medication at night. At 6 weeks of treatment, acne (1.36; 95% confidence interval [CI] 1.09, 1.64; p for interaction = 0.04) and dry skin (1.35; 95% CI 1.09, 1.61, p for interaction = 0.01) in the day group showed a much increase from baseline compared to the night group. In contrast, the night group reported greater reductions in lung cancer-related symptoms from baseline compared to the day. During follow-up (median 43 months), the night group had a lower risk of all-cause death than the day group, especially in younger patients (adjusted hazard ratio = 0.34; 95% CI 0.13, 0.87).

Conclusions: The group taking EGFR-TKIs at night experienced fewer side effects and had longer overall survival compared to the day group. Clinicians should consider recommending that lung cancer patients take their once-daily oral anticancer drugs in the evening rather than the morning to improve treatment outcomes.

Keywords: EGFR-TKIs targeted therapy; circadian rhythm; lung cancer; mortality; symptom.

PubMed Disclaimer

References

    1. Takeda M, Okamoto I, Nakagawa K (2015) Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer 88:74–79. https://doi.org/10.1016/j.lungcan.2015.01.026 - DOI - PubMed
    1. Tadic D, Spasojevic IB, Tomasevic ZI, Dejanovic SD (2015) Oral administration of antineoplastic agents: the challenges for healthcare professionals. J BUON 20:690–698 - PubMed
    1. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Levi FA (2014) The circadian timing system in clinical oncology. Ann Med 46:191–207. https://doi.org/10.3109/07853890.2014.916990 - DOI - PubMed
    1. Ji M, Li XD, Zhang H et al (2014) Report of clinical studies on chronochemotherapy for advanced non-small cell lung cancer in China. Tumour Biol 35:12285–12292. https://doi.org/10.1007/s13277-014-2539-z - DOI - PubMed
    1. Shang Z, Li J (2023) Comparison of clinical efficacy between chrono-chemotherapy and conventional chemotherapy in patients with non-small cell lung cancer. Am J Cancer Res 13:4277–4287 - PubMed - PMC

MeSH terms

LinkOut - more resources